The reiteration of an Outperform rating by a reputable analyst like David Nierengarten from Wedbush is a positive signal for G1 Therapeutics. The maintained price target of $5 also indicates a positive outlook for the stock. This could potentially lead to an increase in the stock's price in the short term.